These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 33514608)
1. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. Lebrett MB; Crosbie EJ; Smith MJ; Woodward ER; Evans DG; Crosbie PAJ J Med Genet; 2021 Apr; 58(4):217-226. PubMed ID: 33514608 [TBL] [Abstract][Full Text] [Related]
2. Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. Hung RJ; Warkentin MT; Brhane Y; Chatterjee N; Christiani DC; Landi MT; Caporaso NE; Liu G; Johansson M; Albanes D; Marchand LL; Tardon A; Rennert G; Bojesen SE; Chen C; Field JK; Kiemeney LA; Lazarus P; Zienolddiny S; Lam S; Andrew AS; Arnold SM; Aldrich MC; Bickeböller H; Risch A; Schabath MB; McKay JD; Brennan P; Amos CI Cancer Res; 2021 Mar; 81(6):1607-1615. PubMed ID: 33472890 [TBL] [Abstract][Full Text] [Related]
3. Lung Cancer Screening by Low-Dose Computed Tomography - Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting. Kaaks R; Delorme S Rofo; 2021 May; 193(5):527-536. PubMed ID: 33212540 [TBL] [Abstract][Full Text] [Related]
4. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460 [TBL] [Abstract][Full Text] [Related]
5. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113 [TBL] [Abstract][Full Text] [Related]
6. Risk-Based lung cancer screening: A systematic review. Toumazis I; Bastani M; Han SS; Plevritis SK Lung Cancer; 2020 Sep; 147():154-186. PubMed ID: 32721652 [TBL] [Abstract][Full Text] [Related]
7. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886 [TBL] [Abstract][Full Text] [Related]
8. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial. Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478 [TBL] [Abstract][Full Text] [Related]
9. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data. Hüsing A; Kaaks R Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286 [TBL] [Abstract][Full Text] [Related]
10. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313 [TBL] [Abstract][Full Text] [Related]
11. Curbing the burden of lung cancer. Urman A; Hosgood HD Front Med; 2016 Jun; 10(2):228-32. PubMed ID: 27178304 [TBL] [Abstract][Full Text] [Related]
12. [Are we on the verge of lung-cancer screening in the Netherlands?]. Smit AA; Moons-Pasic A; Bresser P Ned Tijdschr Geneeskd; 2015; 159():A8933. PubMed ID: 26058769 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317 [TBL] [Abstract][Full Text] [Related]
14. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness. Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416 [TBL] [Abstract][Full Text] [Related]
15. Lung cancer screening and management. Jones GS; Baldwin DR Minerva Med; 2015 Dec; 106(6):339-54. PubMed ID: 26605556 [TBL] [Abstract][Full Text] [Related]
16. Application of risk prediction models to lung cancer screening: a review. Tammemägi MC J Thorac Imaging; 2015 Mar; 30(2):88-100. PubMed ID: 25692785 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of lung MRI in lung cancer screening. Allen BD; Schiebler ML; Sommer G; Kauczor HU; Biederer J; Kruser TJ; Carr JC; Hazen G Eur Radiol; 2020 Mar; 30(3):1738-1746. PubMed ID: 31748855 [TBL] [Abstract][Full Text] [Related]
18. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359 [TBL] [Abstract][Full Text] [Related]
19. Individual and joint contributions of genetic and methylation risk scores for enhancing lung cancer risk stratification: data from a population-based cohort in Germany. Yu H; Raut JR; Schöttker B; Holleczek B; Zhang Y; Brenner H Clin Epigenetics; 2020 Jun; 12(1):89. PubMed ID: 32552915 [TBL] [Abstract][Full Text] [Related]